CTOs on the Move

Connectyx

www.connectyx.com

 
Connectyx is a development-stage biomedical company focusing on novel treatments for rare diseases. In November, the Company announced it is changing its name to Curative Biotechnology, Inc. and has applied for the name change and a trading symbol (CURB) with the Financial Industry Regulatory Authority, Inc., which should take effect in the first quarter of 2021. Connectyx is focused on therapies with potentially accelerated development paths as a result of either the disease, the nature of the therapeutic itself, or the stage of clinical development. At the heart of the Company is a product development engine that rests on our ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.connectyx.com
  • 1825 NorthWest Corporate Boulevard Suite 110
    Boca Raton, FL USA 33431
  • Phone: 800.526.8006

Executives

Name Title Contact Details
Ronald Bordens
Executive Vice President of Technical Operations and Manufacturing Profile

Similar Companies

Mabtech Inc

Mabtech Inc is a Cincinnati, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BlackThorn Therapeutics

BlackThorn Therapeutics is a neurobehavioral health company developing targeted therapeutics, informed by a deep understanding of brain and behavior relationships, to significantly improve patient outcomes.

DEKA BioSciences

Deka BioSciences, Inc. is committed to developing and delivering life-changing medicines to patients with cancer and inflammatory diseases.

MultiPlan

MultiPlan is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ignyta

Ignyta, located in San Diego, California, is a biotechnology company developing precision medicine with integrated Rx/Dx solutions for cancer patients. Its goal is to discover and develop revolutionary new drugs that target activated genes in cancer cells for the customized treatment of cancer patients. The company's present focus is on the development of RXDX-101, its proprietary oral tyrosine kinase inhibitor that targets solid tumor indications, and advancing its novel Spark discovery programs that leverage its proprietary cancer genomic and epigenomic knowledge bases